Fig. 2
Mix + GalCer vaccine confers long-lasting and tumor-specific immunity. a Mix + GalCer treated mice that survived from the first 4TOO tumor challenge (n = 6) were reinjected with 4TOO tumor cells again (4 × 105 cells/mice, iv). Untreated age-matched mice were injected with 4 × 105 4TOO tumor cells (iv). b Mice treated with Mix + GalCer vaccine that survived after the first 4TOO tumor challenge (n = 5) were injected with the syngeneic A20 B-cell lymphoma (1 × 106 cells, sc). Untreated age-matched mice were injected with 1 × 106 cells A20 tumor cells (sc). **p = 0.005